留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

烟碱乙酰胆碱受体作为镇痛靶点的研究进展

诸德源,  王一然,  蔡国君,  徐添颖

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(4): 309-312,375
诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
引用本文: 诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
shu
ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
Citation: ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
shu

烟碱乙酰胆碱受体作为镇痛靶点的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.005
  • 1.

    第二军医大学 长海医院, 上海 200433

  • 2.

    第二军医大学 药学院药理学教研室, 上海 200433

基金项目: 国家自然科学基金青年科学基金项目(81102487);国家科技重大专项"重大新药创制"(2009ZX09303-002);第二军医大学教学改革重点项目(临床医学8年制课程整合-心血管系统,BMB2014016)

Advance in nicotinic acetylcholine receptors as analgesic targets

  • 1.

    Changhai Hospital, Second Military Medical University, Shanghai 200433, China

  • 2.

    Department of pharmacology, Second Military Medical University, Shanghai 200433, China

  • 摘要: 烟碱乙酰胆碱受体(nicotinic acetylcholine receptors, nAChRs)亦称神经型尼古丁受体,在中枢和外周神经系统有广泛表达。该类受体在疼痛的信号调节中发挥重要作用。近几年,人们发现以nAChRs不同亚单位作为靶点的激动剂在多种急性和慢性疼痛模型上显示良好效果,对于发展新型低成瘾性的镇痛药物具有重要的指导意义。nAChRs阳性变构调节剂为进一步提高该类药物的镇痛效能和拓展治疗窗提供了新思路。综述近几年nAChRs与镇痛研究的最新进展,并分析该领域未来的研究热点。
    Abstract: Nicotinic acetylcholine receptors (nAChRs),also known as neuronal nicotinic receptors,are widely expressed throughout the central and peripheral nervous system. nAChRs play crucial roles in pain signaling. Recently, agonists that target specific nAChR subtypes have shown substantial efficacy in a wide range of acute and chronic pain models, contributing to developing novel analgesic drugs with low drug dependence. Positive allosteric modulators offer new approaches for increasing the potency and therapeutic window of these drugs. This review summarizes the advances in nicotinic acetylcholine receptors as analgesic targets and anticipate the future directions in this field.
  • [1] Del Bufalo A, Cesario A, Salinaro G, et al. Alpha9 alpha10 nicotinic acetylcholine receptors as target for the treatment of chronic pain [J]. Curr Pharm Des, 2014, 20(38): 6042-6047.
    [2] Woodcock J. A difficult balance——pain management, drug safety, and the FDA [J]. N Engl J Med, 2009, 361(22): 2105-2107.
    [3] Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence [J]. Clin J Pain, 2008, 24(6): 469-478.
    [4] Smith HS. Opioids and neuropathic pain [J]. Pain Physician, 2012, 15(3 Suppl): ES93-110.
    [5] Corti C. A history of smoking [M]. Montana: Kessinger Publishing, 2007:112.
    [6] Davis L, Pollock LJ, Stone T. Visceral pain [J]. Surg Gynecol Obstetr, 1932, 55: 418-427.
    [7] Sahley TL, Berntson GG. Antinociceptive effects of central and systemic administrations of nicotine in the rat [J]. Psychopharmacology, 1979, 65(3):279-283.
    [8] Garraffo HM, Spande TF, Williams M. Epibatidine: from frog alkaloid to analgesic clinical candidates. A testimonial to true grit! [J]. Heterocycles, 2009, 79: 207-217.
    [9] Rupniak NM, Patel S, Marwood R, et al. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributableto nicotinic agonist activity [J]. Br J Pharmacol, 1994, 113(4): 1487-1493.
    [10] Umana IC, Daniele CA, McGehee DS. Neuronal nicotinic receptors as analgesic targets: it's a winding road [J]. Biochem Pharmacol, 2013, 86(8): 1208-1214.
    [11] Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, et al. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits [J]. Nature, 1999, 398(6730): 805-810.
    [12] Nirogi R, Goura V, Abraham R, et al. α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for pain [J]. Eur J Pharmacol, 2013, 712(1-3): 22-29.
    [13] Rueter LE, Meyer MD, Decker MW. Spinal mechanisms underlying A-85380-induced effects on acute thermal pain [J]. Brain Res, 2000, 872(1-2): 93-101.
    [14] Daly JW, Garraffo HM, Spande TF, et al. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics [J]. Nat Prod Rep, 2000, 17(2): 131-135.
    [15] Bannon AW, Decker MW, Holladay MW, et al. Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors[J]. Science, 1998, 279(5347): 77-81.
    [16] Lynch JJ 3rd, Wade CL, Mikusa JP, et al. ABT-594 (a nicotinic acetylcholine agonist): anti-allodynia in a rat chemotherapy-induced pain model [J].Eur J Pharmacol, 2005, 509(1): 43-48.
    [17] Holladay MW, Wasicak JT, Lin NH, et al. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors [J]. J Med Chem, 1998, 41(4): 407-412.
    [18] Alsharari SD, Freitas K, Damaj MI. Functional role of alpha7 nicotinic receptor in chronic neuropathic and inflammatory pain: studies in transgenic mice [J]. Biochem Pharmacol, 2013, 86(8):1201-1207.
    [19] Gao B, Hierl M, Clarkin K, et al. Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptoragonists in animal models of persistent pain [J]. Pain,2010, 149(1): 33-49.
    [20] Bagdas D, Sonat FA, Hamurtekin E, et al. The antihyperalgesic effect of cytidine-50-diphosphate-choline in neuropathic and inflammatory pain models [J]. Behav Pharmacol, 2011, 22(5-6): 589-598.
    [21] 刘献文, 张宗旺. 尼古丁镇痛作用机制的研究进展 [J]. 国际麻醉学与复苏杂志, 2013, 34(4): 368-370.
    [22] Cordero-Erausquin M, Changeux JP. Tonic nicotinic modulation of serotoninergic transmission in the spinal cord [J]. Proc Natl Acad Sci(USA), 2001, 98(5): 2803-2807.
    [23] Frber L, Stratz T, Brückle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia--a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group [J]. Scand J Rheumatol Suppl, 2000, 113: 49-54.
    [24] Ramirez-Latorre J, Yu CR, Qu X, et al. Functional contributions of alpha5 subunit to neuronal acetylcholine receptor channels [J]. Nature,1996, 380(6572): 347-351.
    [25] Jackson KJ, Sanjakdar SS, Muldoon PP, et al. a3b4*nicotinic acetylcholine receptor subtype mediates nicotine reward and physicalnicotine withdrawal signs independently of the a5 subunit in the mouse[J]. Neuropharmacology, 2013, 70: 228-235.
    [26] Lee CH, Zhu C, Malysz J, et al. a4b2neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of a4b2 nAChR agonists in pain [J]. Biochem Pharmacol, 2011, 82(8):959-966.
    [27] Uteshev VV. The therapeutic promise of positive allosteric modulation of nicotinic receptors [J]. Eur J Pharmacol, 2014, 727: 181-185.
    [28] Zhu CZ, Chin CL, Rustay NR, et al. Potentiation ofanalgesic efficacy but not side effects: co-administration of an alpha4beta2neuronal nicotinic acetylcholine receptor agonist and its positive allostericmodulator in experimental models of pain in rats [J]. Biochem Pharmacol, 2011, 82(8): 967-976.
    [29] Freitas K, Negus SS, Carroll FI, et al. In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model [J]. Br J Pharmacol, 2013, 169(3): 567-579.
  • [1] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3815
  • HTML全文浏览量:  458
  • PDF下载量:  615
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-01-07
  • 修回日期:  2015-05-05

烟碱乙酰胆碱受体作为镇痛靶点的研究进展

doi: 10.3969/j.issn.1006-0111.2015.04.005
  • 1. 第二军医大学 长海医院, 上海 200433
  • 2. 第二军医大学 药学院药理学教研室, 上海 200433
    • 基金项目:  国家自然科学基金青年科学基金项目(81102487);国家科技重大专项"重大新药创制"(2009ZX09303-002);第二军医大学教学改革重点项目(临床医学8年制课程整合-心血管系统,BMB2014016)
  • 收稿日期: 2015-01-07
  • 修回日期: 2015-05-05

摘要: 烟碱乙酰胆碱受体(nicotinic acetylcholine receptors, nAChRs)亦称神经型尼古丁受体,在中枢和外周神经系统有广泛表达。该类受体在疼痛的信号调节中发挥重要作用。近几年,人们发现以nAChRs不同亚单位作为靶点的激动剂在多种急性和慢性疼痛模型上显示良好效果,对于发展新型低成瘾性的镇痛药物具有重要的指导意义。nAChRs阳性变构调节剂为进一步提高该类药物的镇痛效能和拓展治疗窗提供了新思路。综述近几年nAChRs与镇痛研究的最新进展,并分析该领域未来的研究热点。

English Abstract

诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
引用本文: 诸德源, 王一然, 蔡国君, 徐添颖. 烟碱乙酰胆碱受体作为镇痛靶点的研究进展[J]. 药学实践与服务, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
shu
ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
Citation: ZHU Deyuan, WANG Yiran, CAI Guojun, XU Tianying. Advance in nicotinic acetylcholine receptors as analgesic targets[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(4): 309-312,375. doi: 10.3969/j.issn.1006-0111.2015.04.005
shu

    全文HTML

参考文献 (29)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计